RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Anixa Biosciences Stock

Anixa Biosciences P/S 2024

Anixa Biosciences P/S

0

Ticker

ANIX

ISIN

US03528H1095

WKN

A2N6ZF

As of Sep 29, 2024, Anixa Biosciences's P/S ratio stood at 0, a 0% change from the 470.6 P/S ratio recorded in the previous year.

The Anixa Biosciences P/S history

Anixa Biosciences Aktienanalyse

What does Anixa Biosciences do?

Anixa Biosciences Inc is a biotechnology company focused on the development and commercialization of cancer therapeutics. The company is headquartered in San Jose, California and was founded in 1982. The history of Anixa Biosciences Inc began as a subsidiary of VaxGen Inc, a now dissolved biotechnology company. Originally, Anixa focused on the development of vaccines for infectious diseases before shifting its focus to cancer therapeutics. Since 2016, Anixa Biosciences Inc has made rapid progress, particularly in the field of cancer immunotherapy. The company has formed several partnerships with other major pharmaceutical companies such as Cleveland Clinic and OntoChem to accelerate the development of treatments for various types of cancer. Anixa Biosciences Inc's business model is based on the development and commercialization of patented cancer therapeutics. Anixa has specialized in the development of immunotherapeutics based on its own proprietary technology platform. The company has specialized in three areas: cancer detection, immunotherapy, and antibody production. In cancer detection, the company is working on the development of diagnostic tools that enable doctors to detect and treat cancer at an early stage. In the field of immunotherapy, Anixa has developed various therapeutics that stimulate the body's immune system to attack and destroy cancer cells. The company has specifically developed immunotherapeutics that specialize in targeted attacks on cancer cells. In antibody production, Anixa focuses on the development of monoclonal antibodies that specifically target tumor cells. These antibodies can be used to identify and isolate cancer cells. Additionally, they can be used as carriers for drugs to provide targeted therapies against tumor cells. Another product of Anixa Biosciences Inc is the CchekTM blood test, which was developed for the detection of breast, ovarian, and prostate cancer. The blood test is based on the discovery of specific biomarkers that can indicate an increased presence of cancer cells in blood samples. In 2019, Anixa announced its entry into the rapidly growing market for in-vitro diagnostics. This market includes the development and commercialization of diagnostic tools used for disease identification and monitoring disease progression. Anixa plans to expand its expertise in cancer diagnostics to other disease areas such as cardiovascular diseases and neurological diseases. Overall, Anixa Biosciences Inc has a diverse portfolio of products specializing in the development of cancer therapeutics, diagnostic tools, and immune competence. The company works closely with established research and development companies to enhance its technologies and create new products. Anixa positions itself as an innovative and future-oriented company in the biotechnology industry. Anixa Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Anixa Biosciences's P/S Ratio

Anixa Biosciences's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Anixa Biosciences's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Anixa Biosciences's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Anixa Biosciences’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Anixa Biosciences stock

What is the price-to-earnings ratio of Anixa Biosciences?

The price-earnings ratio of Anixa Biosciences is currently 0.

How has the price-earnings ratio of Anixa Biosciences changed compared to last year?

The price-to-earnings ratio of Anixa Biosciences has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Anixa Biosciences high compared to other companies?

Yes, the price-to-earnings ratio of Anixa Biosciences is high compared to other companies.

How does an increase in the price-earnings ratio of Anixa Biosciences affect the company?

An increase in the price-earnings ratio of Anixa Biosciences would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Anixa Biosciences affect the company?

A decrease in the price-earnings ratio of Anixa Biosciences would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Anixa Biosciences?

Some factors that influence the price-earnings ratio of Anixa Biosciences are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Anixa Biosciences pay?

Over the past 12 months, Anixa Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Anixa Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Anixa Biosciences?

The current dividend yield of Anixa Biosciences is .

When does Anixa Biosciences pay dividends?

Anixa Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Anixa Biosciences?

Anixa Biosciences paid dividends every year for the past 0 years.

What is the dividend of Anixa Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Anixa Biosciences located?

Anixa Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Anixa Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Anixa Biosciences from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Anixa Biosciences pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Anixa Biosciences in the year 2023?

In the year 2023, Anixa Biosciences distributed 0 USD as dividends.

In which currency does Anixa Biosciences pay out the dividend?

The dividends of Anixa Biosciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Anixa Biosciences

Our stock analysis for Anixa Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Anixa Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.